OPR - Delayed Quote • USD NVTA Jan 2026 1.500 call (NVTA260116C00001500) Follow 0.0500 0.0000 (0.00%) As of February 5 at 11:30 AM EST. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for NVTA260116C00001500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: NVTA Invitae gets court approval for five-month bankruptcy sale Genetic test maker Invitae files for bankruptcy protection in US Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process Invitae hires advisers, considers bankruptcy: WSJ SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy SoftBank-Backed Medical Genetics Company Invitae Prepares for Bankruptcy Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics Is Invitae Stock a Buy Now? Invitae Completes Sale of Reproductive Health Assets to Natera Invitae sells reproductive health assets amid liquidity concerns Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts
